Table 5.
Characteristics of IBD patients after VDZ discontinuation due to reimbursement restriction.
| Characteristic | CD (n = 28) | UC (n = 42) |
|---|---|---|
| Male | 31 (72.1) | 34 (68.0) |
| Age at baseline, y | 45.4 ± 19.1 | 50.2 ± 14.3 |
| Duration of VDZ treatment, mo | 11.4 ± 5.3 | 11.1 ± 3.2 |
| Treatment outcome at the time of VDZ discontinuation | ||
| CRM | 12 (42.9) | 16 (38.0) |
| MH | 11 (39.3) | 21 (50.0) |
| Follow-up available after VDZ discontinuation, mo | 8.0 ± 6.9 | 8.6 ± 7.1 |
| VDZ retreatment outcome after relapse | 9 | 16 |
| CRS | 8 (88.9) | 15 (93.8) |
| Duration of VDZ treatment, mo | 10.6 ± 8.7 | 6.5 ± 5.6 |
Values are n (%), mean ± SD, or n.
Abbreviations: CD, Crohn’s disease; CRM, clinical remission; CRS, clinical response; IBD, inflammatory bowel disease; MH, mucosal healing; UC, ulcerative colitis; VDZ, vedolizumab.